<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-88807</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Molecular Mechanisms of Inflammation During Exacerbations of Chronic Obstructive Pulmonary Disease</dc:title>
<dc:description xml:lang="en">Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by an inflammatory andsystemic response that increases during exacerbations of the disease (ECOPD), although the mechanismsof this inflammatory process are not well known.Objectives: To explore the inflammatory changes and possible mechanisms during ECOPD.Methods: We determined the inflammatory cell concentrations in blood and sputum, nitric oxide inexhaled air (FeNO), reactive C-reactive protein (CRP) in plasma, cytokines (IL-6, 8, 1 , 10, 12, TNF- )and SLPI and total antioxidant activity (TAS) in blood and sputum, the activity of nuclear kappa B factor(NF-kB) and of the histone deacetylase enzymes (HDAC) in 17 patients during ECOPD, in stable phase andin 17 smoking controls and 11 non- smoking.Results: ECOPD is characterised by higher levels of FeNO (P&lt;.05), plasma CRP (P&lt;.001) and IL-8, IL-1B,IL-10 in sputum (P&lt;.05) compared with stable COPD and controls. The TAS levels in sputum were lowerin the exacerbated than in stable phase (P&lt;.05) although significantly higher than the controls (P&lt;.05).                       These findings were accompanied by a greater activation of NF-kB in sputum macrophages during theECOPD with no changes in the HDAC activity or in the number of neutrophils in sputum, and a statisticallysignificant deterioration (P&lt;.05) of lung function.Conclusions: Changes were observed in different pulmonary and systemic inflammatory markers duringECOPD, that were not completely resolved during stability. However, current treatment does not allowthe modification of HDAC activity, which limits its anti-inflammatory effects(AU)</dc:description>
<dc:creator>Kersul, Ana L</dc:creator>
<dc:creator>Noguera, Aina</dc:creator>
<dc:creator>Cosío, Borja G</dc:creator>
<dc:creator>Agustía, Alvar</dc:creator>
<dc:creator>Serra, Enrique</dc:creator>
<dc:creator>Iglesias, Amanda</dc:creator>
<dc:creator>Ríos, Ángel</dc:creator>
<dc:creator>Forteza, Aina</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Las agudizaciones de la enfermedad pulmonar obstructiva crónica (AEPOC) se caracterizanpor una respuesta inflamatoria pulmonar y sistémica, que persiste tiempo después de la resolución clínica.Los mecanismos de este proceso inflamatorio no son bien conocidos.Objetivos: Investigar los cambios inflamatorios y sus mecanismos durante las agudizaciones de la EPOC.Métodos: Se determinaron las concentraciones de células inflamatorias en sangre y esputo, óxido nítricoen aire exhalado (FeNO), proteína C reactiva (PCR) en plasma, citocinas (interleucinas [IL] 6, 8, 1 , 10,12, TNF- ) y SLPI (inhibidor de la leucoproteasa), marcadores de estrés oxidativo, la actividad del factornuclear kappa B (NF- B) y de la enzima histona deacetilasa (HDAC) a 17 pacientes durante una AEPOC,en fase estable y a 17 controles fumadores y 11 no fumadores.Resultados: Las AEPOC se caracterizaron por presentar niveles elevados de FeNO (p &lt; 0,05), PCR en plasma(p &lt; 0,001) e IL-8, IL-1 , IL-10 en esputo (p &lt; 0,05) y mayor activación de NF- B en macrófagos de esputoen comparación con EPOC estable y controles. Durante la fase estable persisten niveles elevados de estrésoxidativo, SLPI, IL-8, IL-6 y TNF-alfa, sin objetivarse cambios en la actividad HDAC ni en la cantidad deneutrófilos en esputo a pesar de presentar una mejoría significativa (p &lt; 0,05) de la función pulmonar.Conclusiones: Durante las AEPOC se observan cambios en marcadores inflamatorios pulmonares y sistémicosque no se resuelven por completo en fase estable. El tratamiento actual no permite modificar laactividad HDAC lo que limita sus efectos antiinflamatorios(AU)</dc:description>
<dc:source>Arch Bronconeumol;47(4): 176-183, abr. 2011. graf, tab</dc:source>
<dc:identifier>ibc-88807</dc:identifier>
<dc:title xml:lang="es">Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica</dc:title>
<dc:subject>^d28599</dc:subject>
<dc:subject>^d28620</dc:subject>
<dc:subject>^d4634^s22045</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d36008^s22016</dc:subject>
<dc:subject>^d23481^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28903^s22002</dc:subject>
<dc:subject>^d36008^s22032</dc:subject>
<dc:subject>^d23925^s22032</dc:subject>
<dc:subject>^d23282^s22002</dc:subject>
<dc:subject>^d7426^s22016</dc:subject>
<dc:subject>^d2021^s22073</dc:subject>
<dc:subject>^d36008^s22012</dc:subject>
<dc:subject>^d23282^s22073</dc:subject>
<dc:subject>^d13568^s22063</dc:subject>
<dc:subject>^d13568^s22046</dc:subject>
<dc:subject>^d7426^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201104</dc:date>
</metadata>
</record>
</ibecs-document>
